Département de recherche clinique, Centre de lutte contre le Cancer François Baclesse, Avenue du Général Harris, 14000, Caen, France.
Breast Cancer Res Treat. 2011 Feb;125(3):885-91. doi: 10.1007/s10549-010-1165-8. Epub 2010 Sep 17.
For the majority of breast and/or ovarian cancer patients tested for BRCA1/2 genes, mutation screening of the coding regions remains negative. MicroRNAs which negatively regulate mRNA translation by binding to 3' untranslated region (3'UTR) are implicated in cancer. Genetic changes in the 3'UTR of several genes were reported to be associated with higher susceptibility to particular tumor types. The aim of this study was to analyze the BRCA1 3'UTR in patients tested negative for BRCA1/2 deleterious mutations, in order to find variants implicated in the decrease of BRCA1 expression through modification of miRNA binding. Genotyping analyses were performed on genomic DNA of 70 BRCA negatives index cases, selected among patients with breast or ovarian cancer, less than 50 years old, with a strong family history. The co-occurrence of the identified variants with deleterious BRCA1 mutations was then determined in a control population of 210 patients. A luciferase gene reporter assay was used to investigate the impact of the variants on the BRCA1 gene expression. Two novel variants, c.*750A>G and c.*1286C>A, were identified in the 3'UTR of BRCA1 gene, in two patients. The former was found three times in the control population, whereas the latter was absent. The used functional assay did not reveal any effect on the luciferase expression. This study reveals a weak genomic variability in the 3'UTR of the BRCA1 gene. All together, the results led us to classify the variant c.*750A>G as probably neutral, the variant c.*1286C>A remaining unclassified.
对于大多数接受 BRCA1/2 基因检测的乳腺癌和/或卵巢癌患者,编码区的突变筛查仍然呈阴性。通过与 3'非翻译区(3'UTR)结合来负调控 mRNA 翻译的 microRNAs 与癌症有关。据报道,几个基因的 3'UTR 中的遗传变化与特定肿瘤类型的更高易感性相关。本研究旨在分析 BRCA1 3'UTR 中 BRCA1/2 有害突变检测阴性的患者,以寻找通过 miRNA 结合修饰与 BRCA1 表达降低相关的变体。对 70 名 BRCA 阴性指数病例的基因组 DNA 进行了基因分型分析,这些病例是从年龄小于 50 岁、有强烈家族史的乳腺癌或卵巢癌患者中选择的。然后在 210 名对照患者的人群中确定了鉴定变体与有害 BRCA1 突变的共现。使用荧光素酶基因报告基因测定法研究了变体对 BRCA1 基因表达的影响。在 BRCA1 基因的 3'UTR 中,在两名患者中发现了两个新变体 c.*750A>G 和 c.*1286C>A。前者在对照人群中发现了三次,而后者则不存在。使用的功能测定法并未显示对荧光素酶表达有任何影响。本研究揭示了 BRCA1 基因 3'UTR 中较弱的基因组变异性。总的来说,结果使我们将变体 c.*750A>G 归类为可能中性,变体 c.*1286C>A 仍然未分类。